Invention Grant
- Patent Title: Aryl ureas with angiogenisis inhibiting activity
-
Application No.: US14335268Application Date: 2014-07-18
-
Publication No.: US10653684B2Publication Date: 2020-05-19
- Inventor: Jacques Dumas , William J. Scott , James Elting , Holia Hatoum-Makdad
- Applicant: Bayer Healthcare LLC
- Applicant Address: US NJ Whippany
- Assignee: Bayer Healthcare LLC
- Current Assignee: Bayer Healthcare LLC
- Current Assignee Address: US NJ Whippany
- Agency: Millen White Zelano and Branigan, PC
- Main IPC: A61K31/44
- IPC: A61K31/44
Abstract:
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
Public/Granted literature
- US20180296541A9 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY Public/Granted day:2018-10-18
Information query
